BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Type 1 Diabetes KOL Interview – US, Midwest

January 08, 2020

This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, and upcoming therapies in the pipeline. Key marketed and pipeline assets highlighted include Tresiba, Toujeo, and teplizumab.

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.
Disease Group Covered: Metabolic

 Additional Resources:
Back to the top Back to the top